Anti-HIV Treatment Interruptions in HIV Infected Adults in South Africa

Long-term toxicity and the high cost of medications are two problems faced by HIV infected people taking ART. Previous studies in HIV-infected patients suggest that ART with STIs may decrease drug exposure and lessen long-term drug toxicity, while not sacrificing viral suppression and patient health. This study will determine if ART with STIs can maintain the same level of immune function in HIV-infected people as continuous ART. This study will recruit patients in South Africa.

This study will last 3.5 years. At study entry, all participants will begin daily ART consisting of lamivudine, lopinavir/ritonavir, and stavudine. At Month 6, only participants who have responded well to ART (CD4 count greater than 450 cells/uL and viral load less than 50 copies/ml at Month 6) will be randomly assigned to one of two groups. Group 1 participants will participate in STIs during therapy, and Group 2 participants will receive continuous therapy. People in Group 1 will have treatment interruptions of 2, 4, and 8 weeks of duration in between 16-week periods of ART. Group 1 participants will re-initiate therapy if their CD4 count drops below 350 cells or evidence of clinical disease progression is present. Group 2 participants will continue taking ART throughout the study.

At screening, participants will undergo medical history assessment, a physical exam, and magnetic resonance imaging (MRI) and dual energy x-ray absorptiometry (DEXA) scans. There will be at least 22 study visits occurring approximately every 8 weeks, each lasting 45 to 60 minutes. At each study visit, participants will be required to bring any remaining pills with them so adherence can be assessed and will undergo medical assessments. Blood collection will occur at nearly all visits. For female participants, urine collection will occur at all visits. Participants will receive rabies vaccinations at Weeks 16, 17, and 22. A visit at Week 92 will include an MRI and participants will receive a rabies vaccine booster.

Inclusion criteria

• HIV infected
• CD4 count of 200 to 350 cells/mm3 within 60 days of starting study treatment
• Antiretroviral naive. Participants who have received antiretrovirals through postexposure prophylaxis or short course therapy to prevent mother-to-child transmission are eligible for this study.
• Willing to adhere to study treatment
• Willing to be followed for the duration of this study

Exclusion criteria

• History of AIDS-defining illness (CDC category C). Patients with a history of pulmonary tuberculosis are not excluded.
• Newly diagnosed AIDS-defining opportunistic infection or other condition requiring acute therapy at study entry
• Previous therapy with agents with significant myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic, or cytotoxic potential within 30 days prior to study entry
• History of immunomodulatory therapy within 4 weeks prior to screening, or cannot abstain from immunomodulators during the study
• Previously received rabies vaccine
• Current alcohol or drug abuse that, in the opinion of the investigator, may interfere with the study
• Diarrhea (more than 6 stools per day for 7 consecutive days) within 30 days prior to study entry
• Active or suspected acute hepatitis within 30 days of study entry
• Bilateral peripheral neuropathy of Grade 2 or higher at screening
• Inability to tolerate oral medication
• Any clinical condition that, in the opinion of the investigator, would interfere with the study
• Pregnancy or breastfeeding